Trial reportThe Journal of clinical endocrinology and metabolism2011
A dual sugar challenge test for lipogenic sensitivity to dietary fructose.
Trial report in The Journal of clinical endocrinology and metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03783195 (Genetic-specific Effects of Fructose on Liver Lipogenesis), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genetic-specific Effects of Fructose on Liver Lipogenesis
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- The Influence of Different Foods and Food Ingredients on Acute Postprandial Triglyceride Response: A Systematic Literature Review and Meta-Analysis of Randomized Controlled Trials.Advances in nutrition (Bethesda, Md.) · 2020Pooled it
- Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease.The Journal of clinical investigation · 2021Trial
- Sex Differences in HepaticNutrients · 2018Trial
- A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.The American journal of clinical nutrition · 2015Trial
- Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat.The Journal of clinical endocrinology and metabolism · 2015Trial
- Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis.The American journal of clinical nutrition · 2015Trial
- Acute effects of feeding fructose, glucose and sucrose on blood lipid levels and systemic inflammation.Lipids in health and disease · 2014Trial
- Trial
- De novo lipid synthesis in cardiovascular tissue and disease.Atherosclerosis · 2025Review
- Determining the metabolic effects of dietary fat, sugars and fat-sugar interaction using nutritional geometry in a dietary challenge study with male mice.Nature communications · 2023Article
- Liver insulinization as a driver of triglyceride dysmetabolism.Nature metabolism · 2023Review
- Effects of Fructose and Palmitic Acid on Gene Expression inInternational journal of molecular sciences · 2023Article
- Molecular aspects of fructose metabolism and metabolic disease.Cell metabolism · 2021Review
- Metabolic drivers of non-alcoholic fatty liver disease.Molecular metabolism · 2021Review
- Impact of dietary carbohydrate type and protein-carbohydrate interaction on metabolic health.Nature metabolism · 2021Article
- Fructose and metabolic diseases: too much to be good.Chinese medical journal · 2021Article
- The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights.Nutrients · 2021Review
- No Effect of Added Sugars in Soft Drink Compared With Sugars in Fruit on Cardiometabolic Risk Factors: Results From a 4-Week, Randomized Controlled Trial.Frontiers in nutrition · 2021Article
- Excess dietary fructose does not alter gut microbiota or permeability in humans: A pilot randomized controlled study.Journal of clinical and translational science · 2021Article
- Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms.Nutrients · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
contextIncreased hepatic de novo lipogenesis (DNL) in response to dietary sugar is implicated in dyslipidemia, fatty liver, and insulin resistance.
objectiveThe aim of the study was to develop a simple outpatient tolerance test for lipogenic sensitivity to dietary sugar. DESIGN AND
settingIn inpatients given repeated doses of fructose, protocol 1 compared the acute increase in DNL determined from the percentage of palmitate ("new palmitate") and the percentage of isotopically labeled palmitate ("%DNL") in very low-density lipoprotein triglyceride (TG). Protocol 2 compared the increase in new palmitate in outpatients given three different sugar beverages in a randomized crossover design.
participantsThere were 15 lean and overweight volunteers in protocol 1 and 15 overweight volunteers in protocol 2.
interventionsIn protocol 1, subjects received 1.4 g/kg fructose in divided oral doses over 6 h; in protocol 2, subjects received 0.5 g/kg fructose, 0.5 g/kg fructose plus 0.5 g/kg glucose, or 1 g/kg fructose plus 1 g/kg glucose each as a single oral bolus.
main outcome measuresWe measured the increase in DNL by two methods.
resultsAfter repeated doses of fructose, new palmitate was significantly correlated with the increase in %DNL (Δ, r = 0.814; P < 0.001) and with fasting insulin levels (area under the curve, r = 0.754; P = 0.001). After a single sugar dose, new palmitate showed a dose effect and was greater after fructose plus glucose. Very low-density lipoprotein TG and total TG significantly increased in both protocols.
conclusionsA single oral bolus of fructose and glucose rapidly increases serum TG and TG palmitate in overweight subjects. A dual sugar challenge test could prove useful to identify individuals at risk for carbohydrate-induced dyslipidemia and other adverse effects of increased DNL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.